| Clinical Study of U32 in Patients With Acute Myeloid Leukemia (NCT07036250) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2025-07-03 |
| Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma (NCT07453446) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2025-03-04 |
| Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma (NCT07093073) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2025-01-23 |
| Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma (NCT07093086) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2024-11-07 |
| U87 CAR-T in Patients With Advanced Head and Neck Tumors (NCT06614686) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2024-09-20 |
| Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) (NCT06367114) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2024-04-01 |
| Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT05768529) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2023-03-28 |
| U87 CART in Treatment of Advanced Solid Tumor (NCT05605197) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2022-10-19 |
| Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT04825496) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2021-04-09 |
| CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment (NCT05381662) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2018-08-02 |
| PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer (NCT05732948) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2018-08-02 |
| CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT03896854) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2017-10-18 |
| CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. (NCT03614858) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2017-09-01 |